Enjoy complimentary customisation on priority with our Enterprise License!
Below are some of the key findings from the neuroblastoma drugs market analysis:

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the report.
Get a FREE sample now!
Cancer research organizations are working extensively towards the identification of therapeutic targets on tumor cells or within the signaling cascade that leads to tumor growth. In case of patients suffering from neuroblastoma, a cell surface antigen, GD2 (O-acetyl-GD2 ganglioside), is observed to be overexpressed. This is encouraging researchers to come up with specific monoclonal antibodies against GD2. The growing demand for anti-GD2 antibodies is one of the critical reasons that will drive the neuroblastoma drugs market’s growth. An anti-GD2-specific monoclonal antibody called Dinutuximab was the first drug approved for the treatment of neuroblastoma. The increasing sales of anti-GD2 drugs are due to site-specific action of these drugs and they do not pose any cytotoxic effects in the body. Chemotherapy has harmful cytotoxic side effects which will impact the quality of life of neuroblastoma patients. Hence, physicians are switching toward prescribing anti-GD2 monoclonal antibodies for the treatment of neuroblastoma. These factors are driving the growth of neuroblastoma drugs market during the forecast period.
The continual focus on identifying several new tumor targets through improved research of the etiology of neuroblastoma has resulted in the development of novel therapies for the treatment of relapsed refractory neuroblastoma. It is a fatal condition where a patient’s neuroblastoma returns or becomes unresponsive to the treatment. The study of new tumor targets enables the development of novel-antibodies and cell-mediated immunotherapy agents for the condition. This will drive the neuroblastoma drugs market to grow at a CAGR of over 4% during the forecast period. CUDC-904, Ch14.18, and 1311-MIBG are some of the novel therapies under research and development for neuroblastoma.
The neuroblastoma drugs market is moderately concentrated. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, the industry analysis report will allow clients to identify new growth opportunities and design innovative strategies to improve their share in the market.
The report offers a complete analysis of various companies including:
North America will contribute to the highest market share throughout the forecast period. The increasing incidence of neuroblastoma, availability of reimbursement schemes and new drug approvals for the treatment of neuroblastoma are factors responsible for the high growth of the neuroblastoma drugs market in the region.
The chemotherapy segment accounted for the highest market share in the neuroblastoma drugs market. This can be attributed to the inherent advantages of drugs which involve site-specific action. However, the market share of the segment is expected to decline in the forthcoming years due to the harmful cytotoxicity-related side-effects of chemotherapy.
We can help! Our analysts can customize the market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCT
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSIS
PART 15: APPENDIX
PART 16: EXPLORE TECHNAVIO
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.